What types of tumor patients is Pralsetinib suitable for?

Pralsetinib is a selective RET kinase inhibitor mainly used to treat patients with tumors carrying RET gene fusions or mutations. RETGene abnormalities are found in a variety of tumor types, especially in patients with lung cancer, thyroid cancer, and some other solid tumors. Platinib inhibits tumor development by specifically inhibiting RET kinase activity and blocking the growth signals of tumor cells.

In patients with non-small cell lung cancer (NSCLC), the RET fusion gene is a driver mutation, accounting for approximately 1-2% of all NSCLC patients. Platinib is approved for the treatment of patients with RET fusion-positive advanced or metastatic non-small cell lung cancer, particularly after prior therapy. Clinical data show that platinib has a high tumor shrinkage rate and a significant overall response rate in these patients, effectively improving the patients' survival expectations and quality of life.

In addition to lung cancer, Platinib is also widely used to treat thyroid cancers related to RET gene mutations, especially medullary thyroid cancer (MTC) and some differentiated thyroid cancers. In patients with thyroid cancer, RET gene mutation is one of the important carcinogenic mechanisms. Platinib effectively inhibits the proliferation and spread of tumor cells by targeting RET mutations, making it an important treatment option for these patients, especially in cases where surgical treatment is ineffective or relapses. Platinib shows good efficacy.

In addition, Platinib also shows potential therapeutic value in some rare tumors or other solid tumors, especially those carrying RET gene abnormalities. With the development of precision medicine and the popularization of genetic testing technology, more cancer patients can discover RET abnormalities through testing, thereby benefiting from the targeted therapy of Platinib. In the future, platinib is expected to play a role in a wider range of tumor types and promote the development of tumor treatment in the direction of individualization and precision.

Reference materials:https://gavreto.com/